PL3668513T3 - Aktywatory kinazy pirogronianowej do leczenia chorób krwi - Google Patents

Aktywatory kinazy pirogronianowej do leczenia chorób krwi

Info

Publication number: PL3668513T3
Authority: PL; Poland
Prior art keywords: pyruvate kinase; blood disorders; treating blood; kinase activators; activators
Prior art date: 2017-08-15

Application number

PL18779068T

Other languages

English (en)

Inventor

Giovanni Cianchetta

Tao Liu

Anil Kumar PADYANA

Zhihua Sui

Zhenwei CAI

Dawei Cui

Jingjing Ji

Original Assignee

Agios Pharmaceuticals, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-08-15

Filing date

2018-08-15

Publication date

2022-03-21

2018-08-15 Application filed by Agios Pharmaceuticals, Inc. filed Critical Agios Pharmaceuticals, Inc.

2022-03-21 Publication of PL3668513T3 publication Critical patent/PL3668513T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Engineering & Computer Science (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)

PL18779068T 2017-08-15 2018-08-15 Aktywatory kinazy pirogronianowej do leczenia chorób krwi PL3668513T3 (pl)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
CN2017097496		2017-08-15
US201862673533P	2018-05-18	2018-05-18
US201862673526P	2018-05-18	2018-05-18
EP18779068.8A EP3668513B1 (en)	2017-08-15	2018-08-15	Pyruvate kinase activators for use in treating blood disorders
PCT/US2018/000128 WO2019035864A1 (en)	2017-08-15	2018-08-15	PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF BLOOD DISORDERS

Publications (1)

Publication Number	Publication Date
PL3668513T3 true PL3668513T3 (pl)	2022-03-21

Family

ID=63524352

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL18779068T PL3668513T3 (pl)	2017-08-15	2018-08-15	Aktywatory kinazy pirogronianowej do leczenia chorób krwi
PL18766400.8T PL3668512T3 (pl)	2017-08-15	2018-08-15	Modulatory kinazy pirogranianowej i ich zastosowanie

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL18766400.8T PL3668512T3 (pl)	2017-08-15	2018-08-15	Modulatory kinazy pirogranianowej i ich zastosowanie

Country Status (34)

Country	Link
US (8)	US11590132B2 (pl)
EP (4)	EP4026838A1 (pl)
JP (5)	JP7301040B2 (pl)
KR (3)	KR102764124B1 (pl)
CN (3)	CN111032046B (pl)
AU (4)	AU2018316588B2 (pl)
BR (2)	BR112020003254A2 (pl)
CA (2)	CA3072455A1 (pl)
CL (1)	CL2020000375A1 (pl)
CO (2)	CO2020002961A2 (pl)
CR (1)	CR20200123A (pl)
CY (1)	CY1124953T1 (pl)
DK (2)	DK3668512T3 (pl)
EC (1)	ECSP20018487A (pl)
ES (3)	ES2905100T3 (pl)
FI (1)	FI3668512T3 (pl)
HR (2)	HRP20220039T1 (pl)
HU (2)	HUE057178T2 (pl)
IL (3)	IL272599B (pl)
LT (2)	LT3668513T (pl)
MD (1)	MD3668513T2 (pl)
MX (2)	MX2020001833A (pl)
MY (1)	MY204421A (pl)
PE (1)	PE20200724A1 (pl)
PH (1)	PH12020500343B1 (pl)
PL (2)	PL3668513T3 (pl)
PT (2)	PT3668513T (pl)
RS (2)	RS62871B1 (pl)
SG (2)	SG11202001262QA (pl)
SI (2)	SI3668513T1 (pl)
SM (2)	SMT202300146T1 (pl)
TW (3)	TWI796353B (pl)
UA (1)	UA126292C2 (pl)
WO (3)	WO2019035863A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR102007135B1 (ko)	2017-03-20	2019-08-02	포르마 세라퓨틱스 인크.	피루베이트 키나제 (pkr) 활성화제로서의 피롤로피롤 조성물
LT3668513T (lt)	2017-08-15	2022-03-25	Agios Pharmaceuticals, Inc.	Piruvatkinazės aktyvatoriai, skirti panaudoti kraujo sutrikimų gydymui
EP3697354A4 (en)	2017-10-20	2021-06-30	The Regents of The University of Michigan	EYE DISEASE COMPOSITIONS AND METHODS
CN113166060B (zh)	2018-09-19	2024-01-09	诺沃挪第克健康护理股份公司	用丙酮酸激酶激活化合物治疗镰状细胞病
EP3852791B1 (en)	2018-09-19	2024-07-03	Novo Nordisk Health Care AG	Activating pyruvate kinase r
CN113646050A (zh) *	2019-02-13	2021-11-12	安吉奥斯医药品有限公司	噻吩并[3,2-b]吡咯[3,2-d]哒嗪酮衍生物和其作为用于治疗癌症、肥胖和糖尿病相关病症的pkm2衍生物的用途
CN114008147B (zh) *	2019-06-26	2023-05-02	日产化学株式会社	电荷传输性清漆
EP4617276A3 (en)	2019-09-19	2025-11-26	Novo Nordisk Health Care AG	Pyruvate kinase r (pkr) activating compositions
US20230374017A1 (en) *	2020-07-21	2023-11-23	The Regents Of The University Of Michigan	Compositions and methods for activating pyruvate kinase
CN112490502B (zh) *	2020-12-04	2022-01-21	广州天赐高新材料股份有限公司	一种电解液及锂二次电池
US11566030B2 (en)	2021-02-08	2023-01-31	Global Blood Therapeutics, Inc.	Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators
US12128035B2 (en)	2021-03-19	2024-10-29	Novo Nordisk Health Care Ag	Activating pyruvate kinase R
CN118139864A (zh) *	2021-09-30	2024-06-04	西特瑞治疗有限公司	新化合物
US20250108049A1 (en) *	2021-11-16	2025-04-03	Agios Pharmaceuticals, Inc.	Compounds for treating mds-associated anemias and other conditions
CN116159061A (zh) *	2023-03-09	2023-05-26	上海市第十人民医院	丙酮酸激酶m2激活剂在制备预防或治疗心力衰竭的药物中的应用
WO2024238659A1 (en)	2023-05-15	2024-11-21	Agios Pharmaceuticals, Inc.	Crystalline salts or amorphous forms of 2-((1h-pyrazol-3-yl)methyl)-6-((6-aminopyridin-2-yl)methyl)-4-methyl-4,6-dihydro -5h-thiazolo[5',4':4,5]pyrrolo[2,3-d]pyridazin-5-one
WO2025010390A1 (en) *	2023-07-05	2025-01-09	Agios Pharmaceuticals, Inc.	Synthesis of pyruvate kinase activators
WO2025207563A1 (en)	2024-03-27	2025-10-02	Agios Pharmaceuticals, Inc.	Use of a pk activator in the treatment of sickle cell disease

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4405635A (en)	1979-06-18	1983-09-20	Merrell Dow Pharmaceuticals Inc.	4-Aroylimidazol-2-ones and their use as pharmaceuticals
US4883914A (en)	1987-08-17	1989-11-28	American Cyanamid Company	Benzenesulfonyl carboxamide compounds useful as herbicidal agents
CN1193026C (zh)	1999-07-30	2005-03-16	艾博特股份有限两合公司	2－吡唑啉－5－酮
HK1045496B (en)	1999-09-04	2004-10-21	Astrazeneca Ab	Substituted N-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropionamide derivatives that increase pyruvate dehydrogenase activity
EP1972629A1 (en) *	2007-03-23	2008-09-24	Mutabilis SA	New imidazolo-heteroaryl derivatives with antibacterial properties
FR2933983B1 (fr) *	2008-07-15	2010-08-27	Servier Lab	Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
KR20110033299A (ko) *	2008-07-23	2011-03-30	버텍스 파마슈티칼스 인코포레이티드	트리-사이클릭 피라졸로피리딘 키나제 억제제
US8420649B2 (en) *	2008-08-29	2013-04-16	Amgen Inc.	Pyrido[3,2-d]pyridazine-2(1H)-one compounds as p38 modulators and methods of use thereof
EP2344453B1 (en) *	2008-10-09	2016-12-28	The U.S.A. As Represented By The Secretary, Department Of Health And Human Services	Activators of human pyruvate kinase
CA2758071C (en) *	2009-04-06	2018-01-09	Agios Pharmaceuticals, Inc.	Pyruvate kinase m2 modulators, therapeutic compositions and related methods of use
CN102481300B (zh)	2009-06-29	2015-04-15	安吉奥斯医药品有限公司	治疗性化合物和组合物
JP2013525438A (ja)	2010-04-29	2013-06-20	アメリカ合衆国	ヒトピルビン酸キナーゼ活性剤
EA023796B1 (ru)	2010-12-06	2016-07-29	Глэксо Груп Лимитед	ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
TWI549947B (zh)	2010-12-29	2016-09-21	阿吉歐斯製藥公司	治療化合物及組成物
PT2704721T (pt)	2011-05-03	2018-06-14	Agios Pharmaceuticals Inc	Ativadores da piruvato-cinase para utilização em terapia
US9388164B2 (en) *	2011-05-03	2016-07-12	Agios Pharmaceuticals, Inc	Methods of using pyruvate kinase activators
CA2834692A1 (en)	2011-05-03	2012-11-08	Agios Pharmaceuticals, Inc.	Pyruvate kinase activators for use in therapy
EP3372230B1 (en)	2011-05-03	2020-08-12	Agios Pharmaceuticals, Inc.	Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
HK1198443A1 (en) *	2011-07-19	2015-04-24	无限药品股份有限公司	Heterocyclic compounds and uses thereof
US20140249150A1 (en) *	2011-10-13	2014-09-04	Agios Pharmaceuticals, Inc	Activators of pyruvate kinase m2 and methods of treating disease
US9921221B2 (en)	2012-07-26	2018-03-20	Joslin Diabetes Center, Inc.	Predicting and treating diabetic complications
WO2014074848A1 (en)	2012-11-08	2014-05-15	Agios Pharmaceuticals, Inc.	Therapeutic compounds and compositions and their use as pkm2 modulators
WO2014118135A1 (en) *	2013-01-30	2014-08-07	Bayer Pharma Aktiengesellschaft	Amidoimidazopyridazines as mknk-1 kinase inhibitors
NZ712180A (en) *	2013-03-13	2017-01-27	Flatley Discovery Lab Llc	Pyridazinone compounds and methods for the treatment of cystic fibrosis
WO2014139144A1 (en) *	2013-03-15	2014-09-18	Agios Pharmaceuticals, Inc.	Therapeutic compounds and compositions
AR097543A1 (es) *	2013-09-06	2016-03-23	Lexicon Pharmaceuticals Inc	COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
CN120647572A (zh)	2017-07-07	2025-09-16	英夫拉索姆有限公司	新颖磺酰胺羧酰胺化合物
LT3668513T (lt)	2017-08-15	2022-03-25	Agios Pharmaceuticals, Inc.	Piruvatkinazės aktyvatoriai, skirti panaudoti kraujo sutrikimų gydymui
PE20200758A1 (es)	2017-08-15	2020-07-27	Inflazome Ltd	Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3
JP2020531433A (ja)	2017-08-15	2020-11-05	アッヴィ・インコーポレイテッド	大環状ｍｃｌ−１阻害剤及び使用の方法
AR112690A1 (es)	2017-08-15	2019-11-27	Agios Pharmaceuticals Inc	Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre
CN113646050A (zh) *	2019-02-13	2021-11-12	安吉奥斯医药品有限公司	噻吩并[3,2-b]吡咯[3,2-d]哒嗪酮衍生物和其作为用于治疗癌症、肥胖和糖尿病相关病症的pkm2衍生物的用途

2018
- 2018-08-15 LT LTEPPCT/US2018/000128T patent/LT3668513T/lt unknown
- 2018-08-15 SG SG11202001262QA patent/SG11202001262QA/en unknown
- 2018-08-15 TW TW107128431A patent/TWI796353B/zh active
- 2018-08-15 US US16/639,081 patent/US11590132B2/en active Active
- 2018-08-15 CR CR20200123A patent/CR20200123A/es unknown
- 2018-08-15 UA UAA202001747A patent/UA126292C2/uk unknown
- 2018-08-15 CN CN201880053325.2A patent/CN111032046B/zh active Active
- 2018-08-15 WO PCT/US2018/000127 patent/WO2019035863A1/en not_active Ceased
- 2018-08-15 PT PT187790688T patent/PT3668513T/pt unknown
- 2018-08-15 FI FIEP18766400.8T patent/FI3668512T3/fi active
- 2018-08-15 PE PE2020000245A patent/PE20200724A1/es unknown
- 2018-08-15 DK DK18766400.8T patent/DK3668512T3/da active
- 2018-08-15 HU HUE18779068A patent/HUE057178T2/hu unknown
- 2018-08-15 BR BR112020003254-9A patent/BR112020003254A2/pt unknown
- 2018-08-15 SM SM20230146T patent/SMT202300146T1/it unknown
- 2018-08-15 PH PH1/2020/500343A patent/PH12020500343B1/en unknown
- 2018-08-15 AU AU2018316588A patent/AU2018316588B2/en active Active
- 2018-08-15 MD MDE20200663T patent/MD3668513T2/ro unknown
- 2018-08-15 WO PCT/US2018/000129 patent/WO2019035865A1/en not_active Ceased
- 2018-08-15 DK DK18779068.8T patent/DK3668513T3/da active
- 2018-08-15 KR KR1020237028222A patent/KR102764124B1/ko active Active
- 2018-08-15 SI SI201830558T patent/SI3668513T1/sl unknown
- 2018-08-15 SG SG11202001353PA patent/SG11202001353PA/en unknown
- 2018-08-15 LT LTEPPCT/US2018/000129T patent/LT3668512T/lt unknown
- 2018-08-15 JP JP2020508455A patent/JP7301040B2/ja active Active
- 2018-08-15 PT PT187664008T patent/PT3668512T/pt unknown
- 2018-08-15 CA CA3072455A patent/CA3072455A1/en active Pending
- 2018-08-15 HR HRP20220039TT patent/HRP20220039T1/hr unknown
- 2018-08-15 EP EP21207073.4A patent/EP4026838A1/en not_active Withdrawn
- 2018-08-15 ES ES18779068T patent/ES2905100T3/es active Active
- 2018-08-15 AU AU2018316587A patent/AU2018316587B2/en active Active
- 2018-08-15 SM SM20220023T patent/SMT202200023T1/it unknown
- 2018-08-15 US US16/639,086 patent/US11464775B2/en active Active
- 2018-08-15 CN CN202310962497.4A patent/CN117186119A/zh active Pending
- 2018-08-15 CN CN201880053315.9A patent/CN111032045B/zh active Active
- 2018-08-15 KR KR1020207007344A patent/KR102717594B1/ko active Active
- 2018-08-15 MY MYPI2020000757A patent/MY204421A/en unknown
- 2018-08-15 CA CA3071993A patent/CA3071993A1/en active Pending
- 2018-08-15 ES ES18766400T patent/ES2944545T3/es active Active
- 2018-08-15 MX MX2020001833A patent/MX2020001833A/es unknown
- 2018-08-15 EP EP18766063.4A patent/EP3668881B1/en active Active
- 2018-08-15 ES ES18766063T patent/ES2966825T3/es active Active
- 2018-08-15 MX MX2020001832A patent/MX2020001832A/es unknown
- 2018-08-15 TW TW111135803A patent/TWI823580B/zh active
- 2018-08-15 EP EP18779068.8A patent/EP3668513B1/en active Active
- 2018-08-15 US US16/639,075 patent/US11364240B2/en active Active
- 2018-08-15 PL PL18779068T patent/PL3668513T3/pl unknown
- 2018-08-15 JP JP2020508498A patent/JP7275107B2/ja active Active
- 2018-08-15 KR KR1020207007346A patent/KR102642408B1/ko active Active
- 2018-08-15 IL IL272599A patent/IL272599B/en unknown
- 2018-08-15 EP EP18766400.8A patent/EP3668512B1/en active Active
- 2018-08-15 WO PCT/US2018/000128 patent/WO2019035864A1/en not_active Ceased
- 2018-08-15 RS RS20220003A patent/RS62871B1/sr unknown
- 2018-08-15 TW TW107128429A patent/TWI790271B/zh active
- 2018-08-15 HU HUE18766400A patent/HUE061910T2/hu unknown
- 2018-08-15 SI SI201830914T patent/SI3668512T1/sl unknown
- 2018-08-15 RS RS20230354A patent/RS64221B1/sr unknown
- 2018-08-15 PL PL18766400.8T patent/PL3668512T3/pl unknown
- 2018-08-15 HR HRP20230452TT patent/HRP20230452T1/hr unknown
- 2018-08-15 BR BR112020003262-0A patent/BR112020003262A2/pt active Search and Examination
2020
- 2020-02-11 IL IL272597A patent/IL272597B/en unknown
- 2020-02-13 CL CL2020000375A patent/CL2020000375A1/es unknown
- 2020-03-12 CO CONC2020/0002961A patent/CO2020002961A2/es unknown
- 2020-03-12 CO CONC2020/0002959A patent/CO2020002959A2/es unknown
- 2020-03-13 EC ECSENADI202018487A patent/ECSP20018487A/es unknown
- 2020-11-19 US US16/952,257 patent/US11040036B2/en active Active
2022
- 2022-01-18 CY CY20221100039T patent/CY1124953T1/el unknown
- 2022-01-27 US US17/586,777 patent/US11872225B2/en active Active
- 2022-04-26 IL IL292530A patent/IL292530B2/en unknown
- 2022-05-16 US US17/744,806 patent/US11957680B2/en active Active
- 2022-12-14 JP JP2022199462A patent/JP2023027276A/ja active Pending
2023
- 2023-01-18 JP JP2023005925A patent/JP7530453B2/ja active Active
- 2023-01-20 US US18/099,311 patent/US12133853B2/en active Active
- 2023-05-03 AU AU2023202772A patent/AU2023202772B2/en active Active
2024
- 2024-07-26 JP JP2024121066A patent/JP2024147805A/ja active Pending
- 2024-08-16 AU AU2024205818A patent/AU2024205818A1/en not_active Abandoned
- 2024-09-12 US US18/882,884 patent/US20250144093A1/en active Pending

Also Published As

Publication number	Publication date
CA3072455A1 (en)	2019-02-21
EP3668513A1 (en)	2020-06-24
CN117186119A (zh)	2023-12-08
IL292530B2 (en)	2023-06-01
PT3668513T (pt)	2022-01-21
TWI823580B (zh)	2023-11-21
PT3668512T (pt)	2023-05-22
PL3668512T3 (pl)	2023-06-19
KR20230127364A (ko)	2023-08-31
AU2024205818A1 (en)	2024-09-05
SMT202300146T1 (it)	2023-07-20
JP7275107B2 (ja)	2023-05-17
AU2018316588B2 (en)	2023-02-02
JP2023027276A (ja)	2023-03-01
WO2019035865A8 (en)	2019-03-28
CR20200123A (es)	2020-06-29
AU2023202772A1 (en)	2023-05-18
KR20200054200A (ko)	2020-05-19
TWI796353B (zh)	2023-03-21
CL2020000375A1 (es)	2020-12-11
HRP20230452T1 (hr)	2023-07-21
WO2019035863A8 (en)	2019-03-28
US11590132B2 (en)	2023-02-28
EP3668881B1 (en)	2023-10-04
SMT202200023T1 (it)	2022-03-21
JP7530453B2 (ja)	2024-08-07
CO2020002961A2 (es)	2020-04-13
CO2020002959A2 (es)	2020-04-13
TW202323258A (zh)	2023-06-16
KR102717594B1 (ko)	2024-10-14
UA126292C2 (uk)	2022-09-14
JP2023052478A (ja)	2023-04-11
BR112020003254A2 (pt)	2020-10-27
MX2020001833A (es)	2020-07-22
ES2905100T3 (es)	2022-04-07
CN111032045B (zh)	2023-08-15
SG11202001353PA (en)	2020-03-30
PH12020500343B1 (en)	2024-02-21
US11364240B2 (en)	2022-06-21
WO2019035864A1 (en)	2019-02-21
IL272599A (en)	2020-03-31
SG11202001262QA (en)	2020-03-30
US20210130371A1 (en)	2021-05-06
AU2018316587A1 (en)	2020-02-20
RS62871B1 (sr)	2022-02-28
WO2019035864A8 (en)	2019-03-28
HRP20220039T1 (hr)	2022-04-15
IL272597A (en)	2020-03-31
IL292530A (en)	2022-06-01
FI3668512T3 (fi)	2023-05-12
CN111032046A (zh)	2020-04-17
CY1124953T1 (el)	2023-01-05
KR102642408B1 (ko)	2024-02-28
RU2020110573A3 (pl)	2021-12-24
US20250144093A1 (en)	2025-05-08
TW201920203A (zh)	2019-06-01
EP3668512B1 (en)	2023-02-15
US20210077490A1 (en)	2021-03-18
EP3668512A1 (en)	2020-06-24
RU2020110573A (ru)	2021-09-16
EP3668881A1 (en)	2020-06-24
CN111032046B (zh)	2023-09-26
AU2018316587B2 (en)	2023-05-11
TW201919631A (zh)	2019-06-01
JP2020531443A (ja)	2020-11-05
DK3668512T3 (da)	2023-05-22
SI3668513T1 (sl)	2022-04-29
JP2024147805A (ja)	2024-10-16
TWI790271B (zh)	2023-01-21
DK3668513T3 (da)	2022-01-10
MX2020001832A (es)	2020-07-22
RS64221B1 (sr)	2023-06-30
AU2023202772B2 (en)	2024-05-16
US11040036B2 (en)	2021-06-22
EP4026838A1 (en)	2022-07-13
JP2020531432A (ja)	2020-11-05
US20230226055A1 (en)	2023-07-20
HUE061910T2 (hu)	2023-08-28
US20220233541A1 (en)	2022-07-28
US11872225B2 (en)	2024-01-16
IL272597B (en)	2022-06-01
KR102764124B1 (ko)	2025-02-05
HUE057178T2 (hu)	2022-04-28
MY204421A (en)	2024-08-28
US20200207785A1 (en)	2020-07-02
EP3668513B1 (en)	2021-11-10
PH12020500343A1 (en)	2021-02-08
ES2966825T3 (es)	2024-04-24
SI3668512T1 (sl)	2023-06-30
IL272599B (en)	2022-08-01
US20200206225A1 (en)	2020-07-02
LT3668512T (lt)	2023-06-12
KR20200054199A (ko)	2020-05-19
JP7301040B2 (ja)	2023-06-30
WO2019035863A1 (en)	2019-02-21
ECSP20018487A (es)	2020-05-29
BR112020003262A2 (pt)	2020-09-01
US11464775B2 (en)	2022-10-11
WO2019035865A1 (en)	2019-02-21
CN111032045A (zh)	2020-04-17
CA3071993A1 (en)	2019-02-21
LT3668513T (lt)	2022-03-25
MD3668513T2 (ro)	2022-04-30
PE20200724A1 (es)	2020-07-21
AU2018316588A1 (en)	2020-02-20
US20220395503A1 (en)	2022-12-15
ES2944545T3 (es)	2023-06-22
US12133853B2 (en)	2024-11-05
US11957680B2 (en)	2024-04-16

Publication	Publication Date	Title
IL292530B2 (en)	2023-06-01	Pyruvate kinase activators for use in the treatment of blood disorders
IL288231A (en)	2022-01-01	An inhibitor of jak1/2 or a pharmaceutical salt derived from it and an inhibitor of pi3k or a pharmaceutical salt derived from it, for use in the treatment of myelofibroblasts.
HRP20210518T1 (hr)	2021-05-14	Derivati 2,4-tiazolidindiona, namijenjeni liječenju poremećaja središnjeg živčanog sustava
IL256166B (en)	2020-10-29	Compounds for use in the treatment of neuromuscular disorders
SI3882250T1 (sl)	2023-07-31	Tetrahidropiranil amino-pirolopirimidinon za uporabo pri zdravljenju z BTK posredovanih motenj
LT3472153T (lt)	2021-12-27	Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme
ZA201902320B (en)	2022-11-30	17alpha,21-diesters of cortexolone for use in the treatment of tumors
IL271020A (en)	2020-01-30	Tinostemustine for the treatment of sarcoma
HUE039750T2 (hu)	2019-02-28	Hidroxi-buspiron mozgászavarok kezelésére
GB201702160D0 (en)	2017-03-29	Inhibitors for use in therapy
ZA201802399B (en)	2020-01-29	Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use in the treatment of cancer
IL253933A0 (en)	2017-10-31	History of pyrimidine use in the treatment of cancer
ZA202006886B (en)	2022-07-27	R-fadrozole for use in the treatment of aldostonerism
GB201615844D0 (en)	2016-11-02	Agents for use in therapy
HK40030323A (en)	2021-02-26	Pyruvate kinase activators for use in treating blood disorders